Yokukansan and its ingredients as possible treatment options for schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1629-1634

  Yu, Chuan Hsun ^a   Ishii, Ryouhei ^b   Yu, Shun Chieh ^a   Takeda, Masatoshi ^b  

^a Yuli Hospital Department of Health Taiwan   (Taiwan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; D2 receptor; Geissoschizine methyl ether; Glycyrrhizin; Herbal medicine

Indexed keywords

ACETYLCHOLINE; ANGELICA ACUTILOBA EXTRACT; ATRACTYLODES EXTRACT; BUPLEURUM FALCATUM EXTRACT; CLOZAPINE; CNIDIUM OFFICINALE EXTRACT; GEISSOSCHIZINE; GLYCYRRHIZA URALENSIS EXTRACT; KAMPO; OLANZAPINE; PLANT EXTRACT; PORIA COCOS EXTRACT; QUETIAPINE; RISPERIDONE; SEROTONIN; UNCARIA RHYNCHOPHYLLA EXTRACT; UNCLASSIFIED DRUG; YOKUKANSAN;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ABSENCE OF SIDE EFFECTS; ANGELICA; ANGELICA ACUTILOBA; ATRACTYLODES; ATRACTYLODES LANCEA; BARNES AKATHISIA SCALE; BRIEF PSYCHIATRIC RATING SCALE; BUPLEURUM; BUPLEURUM FALCATUM; CHARLES BONNET SYNDROME; CHINESE MEDICINE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); CNIDIUM; CNIDIUM OFFICINALE; CONSTIPATION; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOM SCALE; DRUG STRUCTURE; EPIGASTRIC DISCOMFORT; FATIGUE; GLYCYRRHIZA URALENSIS; HUMAN; HYPOKALEMIA; LEG EDEMA; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NONHUMAN; OPEN STUDY; PLANT ROOT; PORIA COCOS; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIMPSON ANGUS SCALE; TARDIVE DYSKINESIA; TREMOR; UNCARIA; UNCARIA RHYNCHOPHYLLA;

EID: 84907363435     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S67607     Document Type: Review

References (56)

1. Andreasen NC. Understanding the causes of schizophrenia. N Engl J Med. 1999;340(8):645-647.
2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330.
3. Venables PH. Input dysfunction in schizophrenia. Prog Exp Pers Res. 1964;72:1-47.
4. Park S, Holzman PS, Goldman-Rakic PS. Spatial working memory deficits in the relatives of schizophrenic patients. Arch Gen Psychiatry. 1995;52(10):821-828.
5. Freedman R. Schizophrenia. N Engl J Med. 2003;349(18): 1738-1749.
6. Swanson JW, Holzer CE 3rd, Ganju VK, Jono RT. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry. 1990;41(7): 761-770.
7. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2): 127-135.
8. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081-1090.
9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
10. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989;99 Suppl:S18-S27.
11. Matsubara S, Meltzer HY. Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci. 1989; 45(15):1397-1406.
12. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32(1): 67-77.
13. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23(4):663-674.
14. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
15. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J Clin Psychiatry. 2005;66(4):534-538.
16. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296.
17. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272.
18. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
19. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131.
20. Aizawa R, Kanbayashi T, Saito Y, et al. Effects of Yoku-kan-san-ka-chimpi-hange on the sleep of normal healthy adult subjects. Psychiatry Clin Neurosci. 2002;56(3):303-304.
21. Iwasaki K, Kobayashi S, Chimura Y, et al. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia. J Am Geriatr Soc. 2004;52(9):1518-1521.
22. Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine YiGan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005;66(2):248-252.
23. Iwasaki K, Kato S, Monma Y, et al. A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc. 2007;55(12):2035-2040.
24. Horiguchi J. [Clinical usage of Yi-gan san-schizophrenia, borderline personality disorder, dyskinesia etc]. Seishin Shinkeigaku Zasshi. 2012;114(6):708-718. Japanese.
25. Okamoto H, Okami T, Ikeda M, Takeuchi T. Effects of Yoku-kan-san on undifferentiated somatoform disorder with tinnitus. Eur Psychiatry. 2005;20(1):74-75.
26. de Caires S, Steenkamp V. Use of Yokukansan (TJ-54) in the treatment of neurological disorders: a review. Phytother Res. 2010;24(9): 1265-1270.
27. Tateno M, Ukai W, Ono T, Saito S, Hashimoto E, Saito T. Neuroprotective effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1704-1707.
28. Mizukami K, Asada T, Kinoshita T, et al. A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol. 2009;12(2):191-199.
29. Kung FC, Ishii R, Liu HC, Takeda M. New possibility of traditional Chinese and Japanese medicine as treatment for behavioral and psychiatric symptoms in dementia. Clin Interv Aging. 2012;7:393-396.
30. Mizukami K. Kampo therapy as an alternative to pharmacotherapy using antipsychotic medicines for behavioral and psychological symptoms of dementia (BPSD). Psychogeriatrics. 2008;8(3):137-141.
31. Miyaoka T, Horiguchi J. Clinical potential of Yi-gan san (Yokikansan) for psychiatric disorders. Curr Psychiatry Rev. 2009;5(4):271-275.
32. Furuya M, Kunishige K J H. [Three case of Lewy body disease with hallucination successfully treated with yi-gan san]. Seishin Igaku. 2007; 49:417-420. Japanese.
33. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):761-764.
34. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin Neuropharmacol. 2009;32(1):6-9.
35. Miyaoka T, Nagahama M, Tsuchie K, et al. Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with Yi-gan san. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2): 382-383.
36. Miyaoka T, Furuya M, Kristian L, et al. Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study. Clin Neuropharmacol. 2011;34(1):24-27.
37. Plummer C, Kleinitz A, Vroomen P, Watts R. Of Roman chariots and goats in overcoats: the syndrome of Charles Bonnet. J Clin Neurosci. 2007;14(8):709-714.
38. Miyaoka T, Wake R, Furuya M, et al. Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: an open-label study. Phytomedicine. 2013;20(7):654-658.
39. Takeda A, Itoh H, Tamano H, Yuzurihara M, Oku N. Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. Nutr Neurosci. 2008;11(1):41-46.
40. Kawakami Z, Kanno H, Ueki T, et al. Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience. 2009;159(4):1397-1407.
41. Kawakami Z, Ikarashi Y, Kase Y. Glycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J Pharmacol. 2010;626(2-3):154-158.
42. Tabuchi M, Imamura S, Kawakami Z, Ikarashi Y, Kase Y. The bloodbrain barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol. 2012;32(7): 1139-1146.
43. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol. 2013;698(1-3):6-18.
44. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev. 2000;31(2-3):302-312.
45. Egashira N, Iwasaki K, Ishibashi A, et al. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1516-1520.
46. Terawaki K, Ikarashi Y, Sekiguchi K, Nakai Y, Kase Y. Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol. 2010;127(2):306-312.
47. Imamura S, Tabuchi M, Kushida H, et al. The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol. 2011;31(5):787-793.
48. Ueda T, Ugawa S, Ishida Y, Shimada S. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. Eur J Pharmacol. 2011;671(1-3):79-86.
49. Glennon RA, Dukat M, Grella B, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000;60(2):121-132.
50. Nishi A, Yamaguchi T, Sekiguchi K, et al. Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin 1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan. Neuroscience. 2012;207:124-136.
51. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11(7):802-812.
52. Galici R, Boggs JD, Miller KL, Bonaventure P, Atack JR. Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol. 2008;19(2):153-159.
53. Uchida N, Takasaki K, Sakata Y, et al. Cholinergic involvement and synaptic dynamin 1 expression in Yokukansan-mediated improvement of spatial memory in a rat model of early Alzheimer's disease. Phytother Res. 2013;27(7):966-972.
54. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26(3):325-339.
55. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561-566.
56. Izumi M, Seki T, Iwasaki K, Sakamoto K. Chinese herbal medicine Yi-Gan San decreases the lipid accumulation in mouse 3T3-L1 adipocytes by modulating the activities of transcription factors SREBP-1c and FoxO1. Tohoku J Exp Med. 2009;219(1):53-62.